本文由小咖机器人翻译整理

期刊来源：Ann Intern Med

原文链接：https://doi.org/10.7326/M23-2956

摘要内容如下：

背景

对副作用的担忧是SARS-CoV-2疫苗犹豫不决的常见原因。

客观

确定SARS-CoV-2信使RNA（mRNA）疫苗接种的短期副作用是否与随后的中和抗体（NAB）应答相关。

设计

前瞻性队列研究。

设置

旧金山湾区。

参与者

未接种SARS-CoV-2疫苗或暴露于SARS-CoV-2的成人，然后接受2剂BNT162B2或mRNA-1273。

测量

第二剂疫苗接种后1个月和6个月的血清NAB滴度。每日症状调查和每次剂量的客观生物测定。

结果

363名参与者被纳入症状相关分析（65.6%为女性；平均年龄为52.4岁[SD，11.9]），147人被纳入生物统计相关分析（66.0%为女性；平均年龄58.8岁[SD，5.3]）。在接种后1个月和6个月，第二次接种后的寒战、疲劳、不适和头痛均与NAB升高1.4至1.6倍相关。在两个随访时间点，症状计数和接种疫苗引起的皮肤温度和心率变化均与NAB呈正相关。第2次给药后皮肤温度每升高1°C，1个月后NAB升高1.8倍，6个月后NAB升高3.1倍。

局限性

该研究于2021年在接受初级疫苗系列的人群中进行，这使得先前接种过SARS-CoV-2疫苗或暴露于SARS-CoV-2的人群的可推广性不明确。观察到的关联是否也适用于针对非祖先SARS-CoV-2毒株的中和活性也是未知的。

结论

趋同的自我报告和客观的生物统计学研究结果表明，SARS-CoV-2 mRNA疫苗接种的短期全身副作用与更大的长期NAB反应相关。这可能与解决对疫苗副作用的消极态度有关，这是疫苗吸收的障碍。

主要资金来源

国家老龄化研究所。

英文原文如下：

Abstracts

BACKGROUND  Concern about side effects is a common reason for SARS-CoV-2 vaccine hesitancy.

OBJECTIVE  To determine whether short-term side effects of SARS-CoV-2 messenger RNA (mRNA) vaccination are associated with subsequent neutralizing antibody (nAB) response.

DESIGN  Prospective cohort study.

SETTING  San Francisco Bay Area.

PARTICIPANTS  Adults who had not been vaccinated against or exposed to SARS-CoV-2, who then received 2 doses of either BNT162b2 or mRNA-1273.

MEASUREMENTS  Serum nAB titer at 1 month and 6 months after the second vaccine dose. Daily symptom surveys and objective biometric measurements at each dose.

RESULTS  363 participants were included in symptom-related analyses (65.6% female; mean age, 52.4 years [SD, 11.9]), and 147 were included in biometric-related analyses (66.0% female; mean age, 58.8 years [SD, 5.3]). Chills, tiredness, feeling unwell, and headache after the second dose were each associated with 1.4 to 1.6 fold higher nAB at 1 and 6 months after vaccination. Symptom count and vaccination-induced change in skin temperature and heart rate were all positively associated with nAB across both follow-up time points. Each 1 °C increase in skin temperature after dose 2 was associated with 1.8 fold higher nAB 1 month later and 3.1 fold higher nAB 6 months later.

LIMITATIONS  The study was conducted in 2021 in people receiving the primary vaccine series, making generalizability to people with prior SARS-CoV-2 vaccination or exposure unclear. Whether the observed associations would also apply for neutralizing activity against non-ancestral SARS-CoV-2 strains is also unknown.

CONCLUSION  Convergent self-report and objective biometric findings indicate that short-term systemic side effects of SARS-CoV-2 mRNA vaccination are associated with greater long-lasting nAB responses. This may be relevant in addressing negative attitudes toward vaccine side effects, which are a barrier to vaccine uptake.

PRIMARY FUNDING SOURCE  National Institute on Aging.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。